YELLOW Sitting out on mixed signals.
Let winners run
Regime: GREEN
The Picks
| Ticker | Scan Price | Gap % | RVOL | Catalyst | ML Hold Prob | ML Expected |
|---|---|---|---|---|---|---|
| TETH | $9.69 | 5.33 | 52.17 | No catalyst identified | — | — |
| HAS | $85.00 | 4.23 | 32.59 | Earnings: Hasbro raised FY2026 sales guidance to $4.936B-$5.030B driven by strong Marvel Super Heroes performance, with earnings scheduled for July 21, 2026. | — | — |
| NUVB | $6.30 | 8.62 | 21.13 | Fda: Nuvation Bio announced positive updated Phase 2 data and trial expansion for safusidenib in newly-diagnosed Grade 2 glioma patients, representing clinical progress toward potential regulatory approval | — | — |
| NU | $14.05 | 3.38 | 19.40 | M&A: Nu Holdings agreed to acquire 100% of Banco Porto Real De Investimentos, adding a banking license to Nubank's Brazilian financial conglomerate. | — | — |
| MMM | $168.60 | 5.48 | 18.62 | Earnings: 3M reported Q2 earnings with tariff headwinds of $110M offset by raised 2026 profit guidance, indicating turnaround momentum despite near-term sector pressures in consumer electronics and auto. | — | — |
The Results
| Ticker | Entry | Entry Time | Exit | Exit Time | Method | P/L | % | Catalyst |
|---|---|---|---|---|---|---|---|---|
| TETH | $9.69 | No catalyst identified | ||||||
| HAS | $85.00 | Earnings: Hasbro raised FY2026 sales guidance to $4.936B-$5.030B driven by strong Marvel Super Heroes performance, with earnings scheduled for July 21, 2026. | ||||||
| NUVB | $6.30 | Fda: Nuvation Bio announced positive updated Phase 2 data and trial expansion for safusidenib in newly-diagnosed Grade 2 glioma patients, representing clinical progress toward potential regulatory approval | ||||||
| NU | $14.05 | M&A: Nu Holdings agreed to acquire 100% of Banco Porto Real De Investimentos, adding a banking license to Nubank's Brazilian financial conglomerate. | ||||||
| MMM | $168.60 | Earnings: 3M reported Q2 earnings with tariff headwinds of $110M offset by raised 2026 profit guidance, indicating turnaround momentum despite near-term sector pressures in consumer electronics and auto. |
Shadow Results
| Ticker | Shadow Entry | Shadow Exit | Exit Time | Method | Shadow P/L | % | Result | Catalyst |
|---|---|---|---|---|---|---|---|---|
| TETH | $9.69 | No catalyst identified | ||||||
| HAS | $85.00 | Earnings: Hasbro raised FY2026 sales guidance to $4.936B-$5.030B driven by strong Marvel Super Heroes performance, with earnings scheduled for July 21, 2026. | ||||||
| NUVB | $6.30 | Fda: Nuvation Bio announced positive updated Phase 2 data and trial expansion for safusidenib in newly-diagnosed Grade 2 glioma patients, representing clinical progress toward potential regulatory approval | ||||||
| NU | $14.05 | M&A: Nu Holdings agreed to acquire 100% of Banco Porto Real De Investimentos, adding a banking license to Nubank's Brazilian financial conglomerate. | ||||||
| MMM | $168.60 | Earnings: 3M reported Q2 earnings with tariff headwinds of $110M offset by raised 2026 profit guidance, indicating turnaround momentum despite near-term sector pressures in consumer electronics and auto. |
Things to Explore
Interested in our research, validation methodology, and trading system?
Get in TouchWork With Diana
Need a context architect to scaffold your AI agents and facilitate structured learning?
Visit goddev.aiThis post is part of a series documenting MorningEdge's development in real time. The knowledge base contains 0 books, papers, and lab reports totaling 0+ searchable chunks. The trading system described is paper trading only — no real capital is at risk.